SteadyMD vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
SteadyMD built B2B telehealth infrastructure with 600+ clinicians in 50 states (~5M revenue); acquired by DocGo (Oct 2025) to become the clinical backend for digital health platforms.
About
SteadyMD was founded in 2016 in St. Louis with a mission to build the infrastructure layer that enables healthcare companies to deliver telehealth services without building clinical operations from scratch. The company recognized that the fastest-growing segment of the telehealth market was not direct-to-consumer care but B2B infrastructure — the clinical staffing, licensing, credentialing, compliance, and workflow systems that other healthcare companies need to operate virtual care programs at scale. SteadyMD built this stack as a managed service, enabling digital health companies, health systems, and employers to launch and scale telehealth programs rapidly.\n\nSteadyMD's platform provides healthcare organizations with access to a network of more than 600 clinicians — physicians, nurse practitioners, and physician assistants — who are licensed across all 50 states and available for virtual care delivery. Clients integrate SteadyMD's clinical workforce and telehealth operating system into their own products, using SteadyMD as an outsourced clinical operations partner rather than building in-house clinician networks. This white-label infrastructure model serves clients across consumer health, chronic disease management, occupational health, and behavioral health — wherever organizations need scalable, compliant clinical capacity without the overhead of direct employment.\n\nSteadyMD was acquired by DocGo in October 2025, a publicly traded mobile health and medical transportation company, in a transaction that brings SteadyMD's telehealth infrastructure capabilities under a larger multimodal healthcare services platform. Prior to the acquisition, SteadyMD generated approximately $25 million in annual revenue, demonstrating durable commercial traction in the B2B telehealth infrastructure segment. The DocGo acquisition positions SteadyMD's technology and clinician network as a foundation for DocGo's expansion into virtual care delivery, combining telehealth infrastructure with DocGo's existing in-person mobile health operations.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.